Chitosan-based drug delivery systems for skin atopic dermatitis: recent advancements and patent trends
Atopic dermatitis (AD) is a complex, relapsing inflammatory skin disease with a considerable social and economic burden globally. AD is primarily characterized by its chronic pattern and it can have important modifications in the quality of life of the patients and caretakers. One of the fastest-growing topics in translational medicine today is the exploration of new or repurposed functional biomaterials into drug delivery therapeutic applications. This area has gained a considerable amount of research which produced many innovative drug delivery systems for inflammatory skin diseases like AD. Chitosan, a polysaccharide, has attracted attention as a functional biopolymer for diverse applications, especially in pharmaceutics and medicine, and has been considered a promising candidate for AD treatment due to its antimicrobial, antioxidative, and inflammatory response modulation properties. The current pharmacological treatment for AD involves prescribing topical corticosteroid and calcineurin inhibitors. However, the adverse reactions associated with the long-term usage of these drugs such as itching, burning, or stinging sensation are also well documented. Innovative formulation strategies, including the use of micro- and nanoparticulate systems, biopolymer hydrogel composites, nanofibers, and textile fabrication are being extensively researched with an aim to produce a safe and effective delivery system for AD treatment with minimal side effects. This review outlines the recent development of various chitosan-based drug delivery systems for the treatment of AD published in the past 10 years (2012–2022). These chitosan-based delivery systems include hydrogels, films, micro-, and nanoparticulate systems as well as chitosan textile. The global patent trends on chitosan-based formulations for the AD are also discussed. Graphical Abstract.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Drug Delivery and Translational Research - 13(2023), 5 vom: 17. Feb., Seite 1436-1455 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chuah, Lay-Hong [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
58.28 / Pharmazeutische Technologie / Pharmazeutische Technologie |
|---|---|
| Themen: |
Atopic dermatitis |
| Anmerkungen: |
© Controlled Release Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s13346-023-01307-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2134448563 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2134448563 | ||
| 003 | DE-627 | ||
| 005 | 20240410115436.0 | ||
| 007 | tu | ||
| 008 | 230510s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13346-023-01307-w |2 doi | |
| 035 | |a (DE-627)OLC2134448563 | ||
| 035 | |a (DE-He213)s13346-023-01307-w-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a 58.28 |2 bkl | ||
| 100 | 1 | |a Chuah, Lay-Hong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chitosan-based drug delivery systems for skin atopic dermatitis: recent advancements and patent trends |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Controlled Release Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Atopic dermatitis (AD) is a complex, relapsing inflammatory skin disease with a considerable social and economic burden globally. AD is primarily characterized by its chronic pattern and it can have important modifications in the quality of life of the patients and caretakers. One of the fastest-growing topics in translational medicine today is the exploration of new or repurposed functional biomaterials into drug delivery therapeutic applications. This area has gained a considerable amount of research which produced many innovative drug delivery systems for inflammatory skin diseases like AD. Chitosan, a polysaccharide, has attracted attention as a functional biopolymer for diverse applications, especially in pharmaceutics and medicine, and has been considered a promising candidate for AD treatment due to its antimicrobial, antioxidative, and inflammatory response modulation properties. The current pharmacological treatment for AD involves prescribing topical corticosteroid and calcineurin inhibitors. However, the adverse reactions associated with the long-term usage of these drugs such as itching, burning, or stinging sensation are also well documented. Innovative formulation strategies, including the use of micro- and nanoparticulate systems, biopolymer hydrogel composites, nanofibers, and textile fabrication are being extensively researched with an aim to produce a safe and effective delivery system for AD treatment with minimal side effects. This review outlines the recent development of various chitosan-based drug delivery systems for the treatment of AD published in the past 10 years (2012–2022). These chitosan-based delivery systems include hydrogels, films, micro-, and nanoparticulate systems as well as chitosan textile. The global patent trends on chitosan-based formulations for the AD are also discussed. Graphical Abstract | ||
| 650 | 4 | |a Atopic dermatitis | |
| 650 | 4 | |a Chitosan | |
| 650 | 4 | |a Chitosan properties | |
| 650 | 4 | |a Hydrogel | |
| 650 | 4 | |a Nanoparticles | |
| 650 | 4 | |a Textile | |
| 650 | 4 | |a Patent | |
| 700 | 1 | |a Loo, Hooi-Leong |4 aut | |
| 700 | 1 | |a Goh, Choon Fu |4 aut | |
| 700 | 1 | |a Fu, Ju-Yen |4 aut | |
| 700 | 1 | |a Ng, Shiow-Fern |0 (orcid)0000-0002-0866-3891 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug Delivery and Translational Research |d Springer US, 2011 |g 13(2023), 5 vom: 17. Feb., Seite 1436-1455 |w (DE-627)767568605 |w (DE-600)2732593-3 |w (DE-576)393435571 |x 2190-393X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:5 |g day:17 |g month:02 |g pages:1436-1455 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s13346-023-01307-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 936 | b | k | |a 58.28 |j Pharmazeutische Technologie |j Pharmazeutische Technologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 5 |b 17 |c 02 |h 1436-1455 | ||